Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25376395 | 0.88 | — | — | |
| SCHEMBL25373735 | 0.84 | — | — | |
| SCHEMBL25374094 | 0.84 | SMN1; SMN2 (0.32) | L3MBTL1SMN1; SMN2L3MBTL3 | |
| SCHEMBL25375398 | 0.82 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL16100073 | 0.77 | — | — | |
| SCHEMBL1005231 | 0.76 | SMN1; SMN2 (0.37) | L3MBTL1SMN1; SMN2L3MBTL3 | |
| SCHEMBL736051 | 0.71 | L3MBTL1 (0.44) | L3MBTL1CYP2A13ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2235706 | 0.67 | L3MBTL1 (0.44) | L3MBTL1CYP2A13ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL738007 | 0.67 | L3MBTL1 (0.40) | L3MBTL1CYP2A13ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25377902 | 0.65 | L3MBTL1 (0.39) | L3MBTL1CYP2A13ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | RAKOVINA THERAPEUTICS INC. (CA) | 2020-09-24 | — | — | US | disclosed |
| EP-2044090-A2 | LUMINESCENT 1-HYDROXY-2-PYRIDINONE CHELATES OF LANTHANIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008797-A2 | LUMINESCENT 1-HYDROXY-2-PYRIDINONE CHELATES OF LANTHANIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | L3MBTL1 2636/4885CYP2A13 4073/4885ALDH1A1 1069/4885 |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | L3MBTL1 2457/4885CYP2A13 4032/4885ALDH1A1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.